Narcisi, Alessandra
 Distribuzione geografica
Continente #
NA - Nord America 890
EU - Europa 269
AS - Asia 122
AF - Africa 28
SA - Sud America 2
OC - Oceania 1
Totale 1.312
Nazione #
US - Stati Uniti d'America 882
CN - Cina 116
FI - Finlandia 69
IE - Irlanda 59
NG - Nigeria 27
FR - Francia 25
IT - Italia 22
SE - Svezia 21
NL - Olanda 18
BE - Belgio 17
DE - Germania 16
GB - Regno Unito 9
RU - Federazione Russa 9
CA - Canada 5
MX - Messico 3
BR - Brasile 2
IN - India 2
JP - Giappone 2
UA - Ucraina 2
AU - Australia 1
IL - Israele 1
LU - Lussemburgo 1
MY - Malesia 1
RO - Romania 1
TN - Tunisia 1
Totale 1.312
Città #
Chandler 245
Shanghai 115
Wilmington 86
Helsinki 69
Dublin 59
Boardman 58
New York 54
San Mateo 45
Ann Arbor 34
Lawrence 34
Princeton 34
Benin City 27
Paris 18
Brussels 17
Leawood 14
Ashburn 11
Amsterdam 10
Fairfield 10
Dallas 9
Dronten 8
London 8
Milan 8
Phoenix 7
Woodbridge 6
Moscow 5
Norwalk 4
Redmond 4
Aguascalientes 3
Bergamo 3
Falkenstein 3
Ottawa 3
San Diego 3
Seattle 3
Chicago 2
Naples 2
Pune 2
Tokyo 2
Toronto 2
Andover 1
Berlin 1
Bollebygd 1
Dundee 1
Florence 1
Frankfurt am Main 1
Gunzenhausen 1
Hangzhou 1
Kemerovo 1
Kuala Lumpur 1
Los Angeles 1
Luxembourg 1
Melegnano 1
Newark 1
Novokuznetsk 1
Sale Marasino 1
São Paulo 1
Tortoreto 1
Tunis 1
Totale 1.046
Nome #
Specific Infiltrate of Hodgkin Lymphoma at Site of Cellulitis Mimicking Secondary Cutaneous Involvement 55
Brodalumab: a new way to inhibit IL-17 in psoriasis 53
S100A8/A9 in psoriatic plaques from patients with psoriatic arthritis 52
Psychiatric comorbidity and suicidal ideation in psoriasis, melanoma and allergic disorders 52
Long-term treatment with adalimumab in psoriatic arthritis: serum adalimumab concentration, immunogenicity and the link with clinical response 47
Programmed cell death in the skin 46
Long-term safety of etanercept in psoriasis: Retrospective study focused on infections 45
Clinical course of COVID-19 in 41 patients with immune-mediated inflammatory diseases: Experience from humanitas center, Milan 45
Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey 41
A fatal case of COVID-19 infection presenting with an erythema multiforme-like eruption and fever 40
Biologic therapies for plaque type psoriasis in patients with previous malignant cancer: long-term safety in a single- center real-life population 39
Long-term safety and efficacy of adalimumab in psoriasis: a multicentric study focused on infections (connecting study) 39
Diagnostic imaging: Listening in to skin disease 35
Complicated coronavirus disease 2019 (COVID-19) in a psoriatic patient treated with ixekizumab 34
noveaux horizon therapeutiques pour le prurit dermatologique au delà de la dermatite atopique: role de i-modulia 34
Measuring psoriatic disease in clinical practice. An expert opinion position paper 34
Effects of TNF-α inhibition on pre-clinical enthesitis: observational study on 49 psoriatic patients 32
Anti-IL17 and anti-IL23 biologic drugs for scalp psoriasis: A single-center retrospective comparative study 32
Palmar nodules in a young woman with ulcerative colitis and enteropathic arthritis 31
Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study 30
Reorganization of a Northern Italy dermatology department during the COVID-19 pandemic: is it temporary or the beginning of a new era in dermatology? 30
Non-complicated evolution of COVID-19 infection in a patient with psoriasis and psoriatic arthritis during treatment with adalimumab 30
TP63 and TP73 in cancer, an unresolved "family" puzzle of complexity, redundancy and hierarchy. 30
Concomitant Pyoderma Gangrenosum-like and Amicrobial Pustulosis of the Folds: a Case Report 30
Generalized pustular psoriasis flare in a patient affected by plaque psoriasis after BNT162b2 mRNA COVID-19 vaccine, successfully treated with risankizumab 29
Urticarial rash in autoinflammatory syndromes 28
Suicide risk and psychiatric comorbidity in patients with psoriasis 28
25-Hydroxyvitamin D serum levels and melanoma risk: a case-control study and evidence synthesis of clinical epidemiological studies 28
Apremilast for the treatment of palmo-plantar non-pustular psoriasis: A real-life single-center retrospective study 26
Impact of delay in follow-up due to COVID-19 pandemic on skin cancer progression: a real-life experience from an Italian hub hospital 23
A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study 21
Fingertip dermatitis: a spy for psoriasis 19
Safety of anti-IL-23 drugs in patients with moderate-to-severe plaque psoriasis and previous tuberculosis infection: a monocentric retrospective study 13
Cutaneous toxicity of CAR T‐cell therapy: Case report of a bullous life‐threatening reaction 11
Skin cancers: how to balance the risks and benefits of surgery during COVID-19 pandemic (a Northern Italy single-center experience) 10
Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real-life clinical practice) study 10
Real-Life Effectiveness and Safety of Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A Single-Center 16-Week Study 9
Pregnancy outcome of a patient treated with upadacitinib for severe atopic dermatitis 9
Dupilumab for the treatment of atopic dermatitis of the elderly: a real-life 52-week experience 9
Pembrolizumab-induced plaque psoriasis successfully treated with risankizumab in a patient with stage IV cutaneous melanoma 9
Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study 8
Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study-IL PSO (Italian landscape psoriasis) 8
Effectiveness and safety of anti-IL-23 and anti-IL-17 biological therapies for psoriasis in elderly patients: Real-world experience from two Italian hospitals 8
Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis) 7
Bullous vasculitis associated with Streptococcus pyogenes sepsis 7
Real-life effectiveness and safety of dupilumab in adolescents with atopic dermatitis: a 52-week single-center retrospective study 7
Anti-IL-23 and anti-IL-17 drugs for the treatment of non-pustular palmoplantar psoriasis: a real-life retrospective study 7
Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis) 7
Tralokinumab rapidly improves subjective symptoms and quality of life in patients with moderate-to-severe atopic dermatitis: a real-life 16-week experience 6
A risankizumab super responder profile identified by long-term real-life observation-IL PSO (ITALIAN LANDSCAPE PSORIASIS) 6
Sub-erythrodermic psoriasis successfully treated with bimekizumab: A case report 6
Biologics for the Treatment of Severe Acrodermatitis Continua of Hallopeau: Report of Two Cases Successfully Treated with Ixekizumab and Ustekinumab 5
Risankizumab for the Treatment of Palmoplantar Pustular Psoriasis: a Report of Two Cases 5
Effectiveness of risankizumab in plaque psoriasis with involvement of difficult-to-treat areas: a real-world experience from two referral centers 5
What Can IBD Specialists Learn from IL-23 Trials in Dermatology? 5
Effectiveness and Safety of Upadacitinib in the Treatment of Moderate-Severe Atopic Dermatitis: A Multicentric, Prospective, Real-World, Cohort Study 4
Safety of Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Viral Hepatitis: A Monocentric Retrospective Study 4
Intra-Class Switch Among IL-23 Inhibitors for Plaque Psoriasis: Is It Worth It? 4
Long-term management of pediatric psoriasis with ixekizumab: a case report 4
Monkeypox infection with perianal lesions, fever, and lymphadenopathy 4
The impact of biologic therapy for moderate-to-severe psoriasis on the immune responses to SARS-CoV-2 infection and vaccination 3
A severe psoriasis flare after COVID-19 treated with risankizumab: complete skin clearance after 16 weeks 3
Effectiveness and safety of upadacitinib for moderate‐to‐severe atopic dermatitis in a real‐world setting: A 52‐week retrospective study 3
Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS) 3
Upadacitinib for the treatment of concomitant psoriasis and atopic dermatitis: a case series 3
Real life long‐term efficacy and safety of ixekizumab in moderate‐to‐severe psoriasis: A 192 weeks multicentric retrospective study-IL PSO(Italian landscape psoriasis) 3
New-onset and flares of psoriasis after COVID-19 infection or vaccination successfully treated with biologics: a case series 3
Upadacitinib for the treatment of atopic dermatitis in the elderly: an Italian case series of seven patients 3
Apremilast for the treatment of pustular psoriasis induced by neoadjuvant ifosfamide + etoposide chemotherapy for Ewing Sarcoma: a case report 3
Risankizumab for the treatment of genital psoriasis: A 1‐year, real‐world experience 2
Anti-IL17 and anti-IL23 biologic drugs for genital psoriasis: a single-center retrospective comparative study 2
Effectiveness and Safety of Biological Therapies in Very Severe Plaque Psoriasis: A Real-Life Retrospective Study 2
Effectiveness of ixekizumab for the treatment of moderate‐to‐severe plaque psoriasis with involvement of difficult‐to‐treat areas: A 52‐week multicenter retrospective study 2
Atypical facial pustular folliculitis by Klebsiella pneumoniae: a case report 2
Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience 1
Safety of Interleukin Inhibitors in Patients with Plaque Psoriasis and Neoplasm: A Retrospective Study from Two Referral Centers 1
Totale 1.374
Categoria #
all - tutte 10.650
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.650

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201 0 0 0 0 0 0 0 0 0 0 0 1
2020/2021157 2 4 0 0 1 45 21 13 35 19 0 17
2021/2022154 2 0 5 31 1 0 9 21 13 17 46 9
2022/2023609 82 48 46 87 59 45 1 48 99 47 41 6
2023/2024453 25 49 126 27 15 60 60 66 16 9 0 0
Totale 1.374